HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sharma, D Articles by Anania, F A Search for Related Content PubMed PubMed Citation Articles by Sharma, D Articles by Anania, F A

Winship Cancer Institute, 1701 Uppergate Drive, Clinic C, Emory University School of Medicine, Atlanta, Georgia 30322, USA
¹ Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

(Requests for offprints should be addressed to D Sharma; Email: dsharma{at}emory.edu)

An increase in the risk of cancer is one of the consequences of obesity. The predominant cancers associated with obesity have a hormonal basis and include breast, prostate, endometrium, colon and gall-bladder cancers. Leptin, the key player in the regulation of energy balance and body weight control also acts as a growth factor on certain organs in both normal and disease states. Therefore, it is plausible that leptin acts to promote cancer growth by acting as a mitogenic agent. However, a direct role for leptin in endometrial cancer has not been demonstrated. In this study, we analyzed the proliferative role of leptin and the mechanism(s) underlying this action in endometrial cancers which express both short and long isoforms of leptin receptors. Treatment with leptin resulted in increased proliferation of ECC1 and Ishikawa cells. The promotion of endometrial cancer cell proliferation by leptin involves activation of STAT3 and ERK2 signaling pathways. Moreover, leptin-induced phosphorylation of ERK2 and AKT was dependent on JAK/STAT activation. Therefore blocking its action at the JAK/STAT level could be a rational therapeutic strategy for endometrial carcinoma in obese patients. We also found that leptin potently induces invasion of endometrial cancer cells in a Matrigel invasion assay. Leptin-stimulated invasion was effectively blocked by pharmacological inhibitors of JAK/STAT (AG490) and phosphatidylinositol 3-kinase (LY294002). Taken together these data indicate that leptin promotes endometrial cancer growth and invasiveness and implicate the JAK/STAT and AKT pathways as critical mediators of leptin action. Our findings have potential clinical implications for endometrial cancer progression in obese patients.

This article has been cited by other articles:

				M. L. Gruen, M. Hao, D. W. Piston, and A. H. Hasty Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1481 - C1488. [Abstract] [Full Text] [PDF]

				C. Chen, Y.-C. Chang, C.-L. Liu, T.-P. Liu, K.-J. Chang, and I.-C. Guo Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway Endocr. Relat. Cancer, June 1, 2007; 14(2): 513 - 529. [Abstract] [Full Text] [PDF]

				N. K. Saxena, D. Sharma, X. Ding, S. Lin, F. Marra, D. Merlin, and F. A. Anania Concomitant Activation of the JAK/STAT, PI3K/AKT, and ERK Signaling Is Involved in Leptin-Mediated Promotion of Invasion and Migration of Hepatocellular Carcinoma Cells Cancer Res., March 15, 2007; 67(6): 2497 - 2507. [Abstract] [Full Text] [PDF]